misleading statements

Rosen Law Firm alerts investors in multiple securities litigation cases, including $PMI, urging them to secure counsel before critical claim deadlines.

Class action lawsuit filed against $CWH over false inventory and demand statements. Stock fell 25% post-Q3, another 16% after Q4 results revealed inventory corrections and dividend suspension.

Grabar Law Office investigates securities fraud claims against $ASPI, $CWH, $EOSE, and $SLNO for alleged disclosure failures. Long-term shareholders may seek compensation and reforms at no cost.

Robbins Geller launches class action lawsuit against $SNOW, alleging securities fraud over false product efficiency claims and material business disclosures between June 2023 and February 2024.

Securities lawsuit filed against $RGNX for allegedly misleading investors about RGX-111 gene therapy efficacy and safety. Lead plaintiff deadline April 14, 2026.

Aquestive Therapeutics faces securities class action over alleged false FDA approval statements for Anaphylm drug. Stock fell 37% after January 2026 NDA rejection.

Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.

Class action lawsuit filed against $NAAM alleges October 2025 IPO prospectus contained false statements about sales and marketing expenses. Lead plaintiff deadline: April 24, 2026.

Rosen Law Firm pursues class action against Eos Energy Enterprises for alleged false statements about operations and guidance. Investors must act by May 5, 2026 deadline.

ODDITY Tech faces class action lawsuit alleging concealment of ad partner algorithm changes that inflated customer acquisition costs. Stock fell 49% after CEO disclosure on February 25.

Rosen Law Firm files securities class actions against Nektar Therapeutics, Enphase Energy, and Aquestive Therapeutics. Investors have until May 5, 2026 to join.

Rosen Law Firm filed class action against Aquestive Therapeutics alleging false statements about product development and regulatory matters. Eligible investors should act before deadline.

Class action lawsuit filed against $CWH for allegedly making false statements about business operations. Stock fell 24.8% and 16.5% in two separate drops.

Class action lawsuit filed against $CORP alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

Class action lawsuit filed against Mereo BioPharma over alleged misstatements regarding failed Phase 3 clinical trials. Investors have until April 6, 2026, to join.

Navan Inc. faces securities lawsuit over undisclosed marketing expenses. Stock tumbled 60% since October offering; investors have until April 24, 2026 to join class action.

Snowflake Inc. faces securities class action lawsuit alleging false statements about product efficiency and features. Lead plaintiff deadline set for April 27, 2026.

Class action lawsuit filed against $CWH alleging false statements about inventory management capabilities, claiming misleading public disclosures harmed shareholders.

REGENXBIO faces securities lawsuit over alleged misleading RGX-111 gene therapy statements. Lead plaintiff deadline is April 14, 2026.

Portnoy Law Firm files class action against Camping World Holdings for materially false statements regarding inventory management and consumer demand between April 2025 and February 2026.